LPLijian Pang

Lijian Pang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lijian Pang has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical evidence mapping for 54 types of oral Chinese patent medicines used in adult bronchial asthma: predominantly as add-on therapy and partially as monotherapy

    by Miao Yu, Linlin Wang, Yongming Liu, Ruizhi Yu, Jiyu Zou, Jingze Li, Jiaqi Wang, Yixuan Zhao, Zi Wang, Shiyi Wang, et al.

  • Open Access

    Benefits and mechanisms of polysaccharides derived from traditional Chinese medicine for ulcerative colitis treatment (Review)

    by Yuebo Jia, Zheng Jiao, Lingshuo Bai, Gege Li, Lijian Pang

    Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by abdominal pain, diarrhea and bloody mucopurulent stools. The UC global incidence is rising and conventional therapies remain limited. Therefore, there is an urgent need for novel treatments. Polysaccharides derived from traditional Chinese medicine (TCM) have emerged as promising candidates due to their multifaceted bioactivities. Preclinical studies have demonstrated that these polysaccharides can regulate immune system pathways, thereby reducing intestinal inflammation and oxidative stress. This protects the intestinal mucosal barrier, enhances tight junction protein expression and modulates the gut microbiota. However, their precise molecular targets and structure‑activity associations remain to be fully elucidated. Translational advancement is currently constrained by challenges such as undefined mechanisms, poor oral bioavailability and a lack of clinical validation. Therefore, the present review focused on a number of polysaccharides derived from TCM herbs. The aim of the present review was to systematically analyze their functions and mechanisms for UC prevention and treatment, thus underscoring the necessity for integration of mechanistic discovery with innovative delivery strategies to facilitate the clinical translation of TCM polysaccharides in UC management.

  • Open Access

    Viral Pathogens and Pulmonary Fibrosis: EMT‐Driven Mechanisms and Insights From Traditional Chinese Medicine

    by Ningzi Zang, Yingxu Wu, Pin Li, Yongming Liu, Shiwen Wang, Jiapeng Leng, Libin Zhan, Xiaodong Lyu, Lijian Pang, Jiaran Wang

    Idiopathic pulmonary fibrosis (IPF) is a serious progressive complication of the respiratory system, which is profoundly associated with persistent extracellular matrix (ECM) deposition, fibrosis, and disrupted tissue regeneration. Emerging evidence shows that epithelial–mesenchymal transition (EMT) acts as a key factor in the pathogenesis of this idiopathic interstitial lung disease by connecting long‐lasting epithelial damage to fibroblast accumulation and fibrotic processes. Viral pathogens, particularly emerging and re‐emerging viruses, such as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2), Influenza Virus, and Dengue Virus (DENV) and also those with oncogenic potential such as Epstein–Barr Virus (EBV), Cytomegalovirus (CMV), and Hepatitis C Virus (HCV), have been demonstrated to be significantly associated with impaired epithelial signalling, persistent inflammation, and EMT induction. This underscores the presence of potential mechanistic overlap between viral infections and fibrotic complications of the respiratory system. On the other hand, investigations have also suggested the capacity of Traditional Chinese Medicine (TCM) agents to modulate various EMT‐linked pathways, which are simultaneously involved in both viral infections and IPF development. These common signalling pathways include TGF‐β, Wnt/β‐catenin, PI3K/AKT, and NF‐κB signalling, acting as potential therapeutic targets against fibrotic complications such as IPF. The present review aims to comprehensively describe current evidence on the dynamic cross‐talk between viral pathogens, particularly SARS‐CoV‐2, Influenza Virus, and DENV, EMT, and lung fibrosis. Additionally, it critically discusses how TCM‐derived bioactive agents can interfere with these interconnected processes. This review elucidates the mechanistic basis and therapeutic potential of TCM compounds in lung fibrosis, considering the wider context of virus‐related EMT dysregulation.


  • Open Access

    Plasma proteins and the risk of inflammatory bowel diseases: A two-sample Mendelian randomization study

    by Zheng Jiao, Ge-Ge Li, Ling-Shuo Bai, Jian-Zeng Guo, Li-Jian Pang

    Dysregulated plasma proteins are therapeutic targets for inflammatory bowel disease (IBD), which is a major global health burden. There is limited causal evidence for these associations. Mendelian randomization (MR) was applied to assess the genetic links between plasma proteins and IBD risk. Genetic instruments for 3282 plasma protein phenotypes were derived from genome-wide association studies (GWAS). Summary statistics from IBD GWAS (overall, Crohn disease [CD] and ulcerative colitis [UC]) were analyzed via inverse-variance weighted (IVW) regression, estimating odds ratios (OR) and 95% confidence intervals (CI). Four proteins showed associations with overall IBD risk: erythrocyte band 7 integral membrane protein (OR = 0.84, 95% CI = 0.77–0.90), Interleukin-1 receptor-like 1 (IL1RL1; OR = 1.07, 1.04–1.10), Interleukin-18 receptor 1 (IL18R1; OR = 1.08, 1.04–1.12), and alcohol dehydrogenase 1 B (ADH1B; OR = 0.85, 0.79–0.91). Subtype analyses revealed CD-specific associations with erythrocyte band 7 (OR = 0.82, 0.76–0.90) and IL1RL1 (OR = 1.10, 1.05–1.14), while UC risk correlated with ADH1B (OR = 0.85, 0.78–0.91) and high-affinity immunoglobulin gamma Fc receptor I (FCGR1A; OR = 0.82, 0.75–0.90). This MR study identified causal associations between specific plasma proteins (erythrocyte band 7, IL1RL1, IL18R1, ADH1B, and FCGR1A) and IBD pathogenesis, with distinct molecular profiles for CD and UC. These findings implicate dysregulated innate immunity and metabolic pathways, offering mechanistic insights into therapeutic development. Further validation of protein-mediated mechanisms is warranted.

  • Open Access

    Evidence map analysis of clinical studies on 42 commonly used oral Chinese patent medicines for the treatment of stable chronic obstructive pulmonary disease

    by Jingze Li, Quan Yuan, Ruizhi Yu, Lijian Pang, Tianjiao Wang, Ningzi Zang, Linlin Wang, Zhongxue Zhao, Lingyun Zhu, Can Yang, et al.


  • Open Access

    The study for asthma in older adults: a combined analysis of the effects of occupational asthmagens, high body-mass index and smoking

    by Jia-Qi Wang, Yuan-Yu Liang, Zhong-Xue Zhao, Wei Xie, Wan-Ning Sun, Ji-Yu Zou, Xiao-Dong Lv, Youfu He, Li-Jian Pang

    Background: Asthma remains a significant public health challenge globally, particularly among older adults who face diagnostic complexity, atypical symptom profiles, and frequent comorbidities. Despite global advances in asthma control, little attention has been paid to the evolving composition and geographic disparity of modifiable risk factors in this age group.Methods: We utilized data from the Global Burden of Disease Study 2021 to evaluate the long-term trends (1990–2021) in asthma burden attributable to high body-mass index (BMI), smoking, and occupational asthmagens among adults aged 60 years and older. Key metrics included age-standardized mortality rates (ASMR), age-standardized DALY rates (ASDR), and estimated annual percentage change (EAPC). Stratified analyses were conducted across Socio-demographic Index (SDI) quintiles, gender, and detailed 5-year age subgroups (60–64 to ≥95 years) to assess disparities across socioeconomic development, gender, and aging patterns, with additional stratification by geographic region.Results: From 1990 to 2021, asthma burden attributable to smoking and occupational asthmagens among older adults declined globally, while high BMI-related burden increased in several middle and low SDI regions. In terms of attribution proportion, the proportion of asthma deaths attributable to high BMI increased from 10.89 to 14.4%, with this upward trend being particularly pronounced in high SDI regions. Occupational asthmagens-related burden showed limited decline and remained elevated in low SDI regions. Gender-stratified analysis showed that the risk burden of smoking was higher in older men in Asia, whereas the high BMI-related burden was higher in women in more developed regions.Conclusion: This study demonstrates a structural shift in the composition of asthma risk factors among older adults, with high BMI emerging as a dominant contributor amid declining traditional behavioral risks such as smoking. There are significant differences among regions, age groups and genders. Targeted, region-specific strategies are essential to address these evolving risks and reduce inequities in asthma burden among aging populations.


  • Effect of Qingluo Yin Regulation on the TGF-β1/Smads/miR-7d/HMGA2 Signaling Pathway to Inhibit Epithelial-Mesenchymal Transformation in AE-IPF

    by Jiaran Wang, Ningzi Zang, Dongdong Fan, Jingyu Wang, Pin Li, Mei Wang, Ruizhi Yu, Yuwei Cui, Yingjie Li, Xiaodong Lv, et al.

    Background: Idiopathic pulmonary fibrosis (IPF) is a challenging refractory interstitial lung disease, and acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is a significant contributor to rapid clinical deterioration and mortality associated with IPF. The clinical application of Qingluo Yin can obviously improve the symptoms of wheezing and dyspnea in patients with AE-IPF, but its therapeutic mechanism of clearing heat and detoxifying, eliminating phlegm and dredging channels in the treatment of AE-IPF needs to be further explored. This study aimed to elucidate the therapeutic mechanisms of Qingluo Yin by examining its regulatory effect on miR-let-7d, impacting the transforming growth factor-β1 (TGF-β1)/Smads signaling pathway and inhibiting epithelial-mesenchymal transformation in AE-IPF through animal experiments. Methods: An AE-IPF rat model was established through secondary bleomycin administration. Model effectiveness was evaluated through blood gas analysis and tissue staining. Lung CT and lung function assessments were used to assess lung volume and hypoxia status. The wet-dry weight ratio and lung coefficient were used to observe pulmonary tissue edema and fibrosis. Western blot analysis was used to determine protein expression levels of N-cadherin, alpha-smooth muscle actin (α-SMA), and E-cadherin in rat lung tissue to determine the degree of epithelial-mesenchymal transformation. Real-time Polymerase Chain Reaction (Real-time PCR) and Western blot were used to detect the levels of TGF-β1, Smad2, phosphorylation Smad2 (p-Smad2), Smad3, p-Smad3, high mobility group protein 2 (HMGA2), and miR-let-7d in rats to evaluate the impact of Qingluo Yin on AE-IPF. Results: Histopathological analysis revealed that Qingluo Yin could significantly improve the degree of alveolar inflammation and interstitial fibrosis in rats, alleviate the low partial pressure of arterial blood oxygen and decrease extracellular matrix deposition. Western blot analysis demonstrated that Qingluo Yin could significantly upregulate the expression level of E-cadherin protein and inhibit epithelial-mesenchymal transformation (EMT) (p < 0.05). Real-time PCR and Western blot revealed significant regulatory effects on the TGF-β1/Smads and key molecule miR-let-7d associated with the EMT pathway (p < 0.05). This intervention reduced the expression and transcription levels of TGF-β1, Smad2, Smad3, and HMGA2 proteins (p < 0.05) while targeting the regulation of miR-let-7d to inhibit AE-IPF. Conclusion: Qingluo Yin exhibits the potential to upregulate miR-let-7d, downregulate the expression of transcription factor HMGA2, inhibit the TGF-β1/Smads signaling pathway, and inhibit EMT, thereby presenting a promising therapeutic approach for treating AE-IPF.